• Lipo3K Transfection Reagent: Advancing Gene Expression Studi

  2026-04-20

  Lipo3K Transfection Reagent offers researchers a robust, low-toxicity solution for high-efficiency nucleic acid delivery, even in difficult-to-transfect cells. Its unique enhancer system and proven performance in complex models, like kidney organoids, make it an ideal choice for gene expression and RNA interference workflows requiring precision and reproducibility.

• APOL1 Variants, Splice Isoforms, and APOL3: Mechanisms in Re

  2026-04-20

  This study elucidates how molecular evolution, splice isoforms, and APOL3 interactions shape the cellular effects of APOL1 risk variants, providing new mechanistic insight into their role in trypanolysis and kidney disease. The findings create a more cohesive framework for researchers investigating APOL1-mediated cytotoxicity and potential therapeutic strategies.

• LY2109761: Advancing Translational TGF-β Dual Inhibition

  2026-04-19

  This thought-leadership article unpacks the mechanistic, experimental, and translational promise of LY2109761, a TGF-β receptor type I and II dual inhibitor, for researchers navigating the complexities of cancer progression, therapy resistance, and fibrosis. With critical discussion of Smad2/3 phosphorylation blockade, competitive landscape, and integration of the latest evidence—including the microRNA 424/503 cluster's regulatory role—this piece guides translational teams in leveraging LY2109761 for next-generation discoveries.

• HyperScript™ Reverse Transcriptase: Precision cDNA Synthesis

  2026-04-18

  HyperScript™ Reverse Transcriptase enables robust RNA-to-cDNA conversion even from low-abundance or highly structured RNA, surpassing standard M-MLV enzymes in sensitivity and thermal stability. This article translates cutting-edge research and practical workflows into actionable guidance for qPCR and transcriptomics, with troubleshooting strategies to optimize every step.

• Steroid-Induced Protoplast Lysis: Mechanisms and Antagonists

  2026-04-17

  This study systematically investigates how synthetic antimicrobial steroids induce lysis of bacterial protoplasts, focusing on Sarcina lutea, and explores the protective effects of various stabilizers and antagonists. The findings deepen our understanding of direct steroid-membrane interactions in antimicrobial action, with implications for membrane-targeted drug design and the interpretation of receptor-mediated susceptibility.

• CAF-Mediated Mitochondrial Modulation Drives Chemoresistance

  2026-04-16

  This study reveals how cancer-associated fibroblasts (CAFs) promote chemoresistance in prostate cancer by modulating mitochondrial metabolism via the ANGPTL4-IQGAP1 axis. The findings clarify a paracrine signaling mechanism and highlight new targets for overcoming drug resistance.

• Vardenafil HCl Trihydrate: Reliable PDE5 Inhibition for cGMP

  2026-04-15

  This article provides an evidence-based, scenario-driven guide for using Vardenafil HCl Trihydrate (SKU A4323) in cell viability, proliferation, and smooth muscle assays. Drawing on recent proteomics advances and vendor comparison, it clarifies best practices for PDE5 inhibition assays, highlights the compound’s selectivity and solubility, and guides researchers in robust experimental design.

• Praeruptorin A Inhibits Ferroptosis in Doxorubicin Cardiotox

  2026-04-14

  This study introduces a high-throughput ferrous ion probe screening approach to identify compounds that mitigate doxorubicin-induced cardiomyopathy (DIC) by targeting ferroptosis. The researchers discovered Praeruptorin A as a novel inhibitor of DMT1-mediated iron overload and ferroptotic cell death, offering a new therapeutic avenue for reducing the cardiac side effects of anthracycline chemotherapy.

• Itraconazole: Triazole Antifungal Agent for Candida Research

  2026-04-13

  Itraconazole is a triazole antifungal agent with validated efficacy against biofilm-forming and drug-resistant Candida strains. Its dual action as a CYP3A4 substrate and inhibitor, and its application in antifungal drug interaction studies, make it a critical tool in translational mycology. This article details its mechanisms, evidence benchmarks, and workflow guidance for research use.

• Latrunculin A (SKU B7555): Reliable Actin Assembly Inhibitio

  2026-04-12

  This scenario-driven article addresses laboratory challenges in cytoskeletal research, focusing on how Latrunculin A (SKU B7555) from APExBIO delivers reproducible, evidence-backed solutions for actin cytoskeleton disruption. Researchers will find actionable guidance for experimental design, protocol optimization, and product selection when performing cell viability, proliferation, or cytotoxicity assays.

• Lipoamino Bundle LNPs Enhance mRNA Transfection in Immune Ce

  2026-04-12

  This study introduces lipoamino bundle lipid nanoparticles (LNPs) engineered for selective and efficient mRNA delivery to dendritic cells and macrophages. Through chemical evolution, the authors achieve high spleen targeting and robust transgene expression, providing a significant step forward in nonviral mRNA delivery for immunological research and therapy.

• PPT (Propyl Pyrazole Triol): Optimizing ERα Signaling Assays

  2026-04-11

  PPT (Propyl Pyrazole Triol) empowers precision mapping of estrogen receptor alpha signaling, setting a gold standard for selective ERα agonist research. This guide distills advanced protocol parameters, cross-validates recent biomarker discoveries, and details troubleshooting strategies for translational oncology and endocrine workflows.

• Dextran Sulfate Sodium Salt in Mouse IBD Models: Applied Wor

  2026-04-11

  Dextran sulfate sodium salt (MW 35000-45000) is the benchmark reagent for inducing reproducible colitis in murine models, powering preclinical ulcerative colitis research. This guide delivers protocol enhancements, troubleshooting tactics, and translational insights, integrating new mechanistic findings to advance experimental rigor and therapeutic discovery.

• Ziprasidone Hydrochloride (A5350): Bridging Neuroscience ...

  2026-04-10

  Ziprasidone Hydrochloride, a second-generation antipsychotic and potent GOT1 inhibitor, is redefining the boundaries of translational research by uniting psychopharmacology and cancer metabolism. This article offers a thought-leadership perspective, integrating mechanistic insight, experimental rigor, and strategic guidance for researchers investigating dopaminergic, serotonergic, and metabolic targets in both neuroscience and oncology. Building on recent peer-reviewed advances, validated protocols, and APExBIO’s product strengths, we chart a forward-looking vision for dual-application research and highlight new opportunities beyond conventional product literature.

• Ziprasidone HCl: Optimizing Neuroscience and Oncology Wor...

  2026-04-09

  Ziprasidone Hydrochloride (Ziprasidone HCl) stands out as a dual-action serotonin and dopamine receptor antagonist and GOT1 inhibitor, enabling robust, reproducible workflows in both neuroscience and cancer research. This comprehensive guide details protocol enhancements, advanced applications, and troubleshooting insights—empowering researchers to leverage APExBIO’s high-quality reagent for next-generation experimental results.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page